12:00 AM
 | 
Sep 07, 1999
 |  BC Week In Review  |  Company News  |  Deals

Cambridge Antibody, AstraZeneca deal

Under a six-month extendable collaboration, CAT will use its ProAb technology to isolate antibody research reagents specific for AstraZeneca's cell-surface receptors and intracellular targets,...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >